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Abstract
BACKGROUND: A substantial minority of type 2 diabetes mellitus (T2DM)
patients treated with metformin develop severe gastrointestinal (GI) symptoms
leading to drug discontinuation, depriving them of the potentially cardioprotective
pleiotropic effects of this first-line oral agent. At present, it is unclear
whether treating diabetes without being able to ever use metformin alters
cardiovascular outcomes. PATIENTS AND METHODS: From a population of
773 consecutive T2DM outpatients, the cardiometabolic phenotypes of 83
patients who discontinued metformin due to GI intolerance (Met-Intol cases) were
compared with those of 332 age- and gender-matched metformin-tolerant (Met-
Tol) controls, amounting to a case: control ratio of 1:4. RESULTS: Mean age
(SD) was 70 (13) (male:female: 46:54). Metformin intolerance was associated
with a reduced prevalence of macroangiopathy (P=0.0486), mainly due to a lower
prevalence of CAD (-34%; P=0.0374). Met-Intol cases more often belonged to
blood group A ...
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Abstract
Background.  –  A substantial minority of type 2 diabetes mellitus (T2DM) patients treated with metformin develop severe gastrointestinal (GI)
symptoms leading to drug discontinuation, depriving them of the potentially cardioprotective pleiotropic effects of this first-line oral agent. At
present, it is unclear whether treating diabetes without being able to ever use metformin alters cardiovascular outcomes.
Patients  and  methods.  –  From a population of 773 consecutive T2DM outpatients, the cardiometabolic phenotypes of 83 patients who discontinued
metformin due to GI intolerance (Met-Intol cases) were compared with those of 332 age- and gender-matched metformin-tolerant (Met-Tol) controls,
amounting to a case: control ratio of 1:4.
Results.  – Mean age (SD) was 70 (13) (male:female: 46:54). Metformin intolerance was associated with a reduced prevalence of macroangiopathy
(P  = 0.0486), mainly due to a lower prevalence of CAD (−34%; P  = 0.0374). Met-Intol cases more often belonged to blood group A and subgroup
A Rh+, with 50% and 66% relative increases (P  = 0.0039 and P  = 0.0005), respectively. There were twice as many non-right-handers among the
Met-Intol (18% vs. 9%; P  = 0.0262), and this group also had significantly higher serum ferritin and LDL cholesterol levels. Statins/fibrates were
used by 66%/19% of Met-Tol vs. 48%/18% of Met-Intol (P  = 0.0051 for statins). On the other hand, there were no differences between groups as
regards smoking, diabetes duration, HbA1c, BMI, blood pressure, waist size, fat mass, visceral fat, liver steatosis, the metabolic syndrome, eGFR,
albuminuria, erectile dysfunction and microangiopathy.
Conclusion.  –  Intolerance to metformin represents an unforeseen phenotype in T2DM patients characterized by a low rate of ischaemic heart
disease, left-handedness, ABO group imbalance and an iron load.
© 2013 Elsevier Masson SAS. All rights reserved.
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Résumé
Quel est le phénotype des patients avec intolérance gastro-intestinale à la metformine ?.
Introduction.  –  Une minorité appréciable de patients diabétiques de type 2 (DT2) traités par metformine souffrent d’effets secondaires gastro-
intestinaux (GI) marqués, conduisant à l’arrêt précoce du médicament, et les privant ainsi d’effets pléiotropes potentiellement cardioprotecteurs.
On ignore si un traitement glycémique au long cours excluant d’emblée la metformine altère le devenir cardiovasculaire de ces patients, et si ces
derniers présentent un phénotype particulier.
Patients  et  méthodes.  –  Analyse du phénotype cardiométabolique de 773 DT2 consécutifs, parmi lesquels 83 patients qui ont dû arrêter défini-
tivement toute prise de metformine en raison d’intolérance GI (groupe [Met-INTOL]) ont été comparés à 332 patients DT2 contrôles, tolérant la
metformine, et appariés pour l’âge et le sexe (groupe [Met-Tol]), représentant un rapport cas-témoin de 1:4.
Résultats.  –  L’âge moyen (DS) était de 70 (13) ans et le rapport hommes:femmes 46:54. L’intolérance GI à la metformine était associée à une
nette réduction de prévalence de macroangiopathie (P  0,0486), principalement due à une prévalence moindre de cardiopathie ischémique (−34 % ;
P  0,0374). Les [Met-Intol] appartenaient plus souvent au groupe sanguin A, sous-groupe ARh+ : +50 % et +66 % (P  0,0039 et 0,0005). Il y
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avait deux fois plus de non-droitiers chez les [Met-Intol] (18 % vs 9 % ; P  = 0,0262). Les statines/fibrates étaient prescrites chez 66 %/19 % des
[Met-Tol] vs 48 %/18 % des [Met-Intol] (P  0,0051 pour les statines). Les taux moyens de LDL-C et de ferritine étaient significativement plus
élevés chez les [Met-Intol]. Aucune différence n’était observée entre les groupes concernant : tabagisme ; durée du diabète ; HbA1c ; IMC ; pression
artérielle ; périmètre abdominal ; masse grasse totale et viscérale ; stéatose hépatique ; syndrome métabolique ; filtration glomérulaire ; albuminurie ;
dysfonction érectile ; et microangiopathies.
Conclusion.  –  L’intolérance gastro-intestinale à la metformine représente un phénotype méconnu du DT2, caractérisé par un très faible taux de
cardiopathie ischémique, une présence accrue de gauchers, un déséquilibre ABO et une surcharge en fer.
© 2013 Elsevier Masson SAS. Tous droits réservés.
Mots clés : Metformine ; Diabète de type 2 ; Effets secondaires ; Gastro-intestinal ; Cardiopathie ischémique ; Gaucher ; Groupes ABO ; Ferritine
1.  Introduction
Metformin is currently recommended as a first-line oral
glucose-lowering agent for type 2 diabetes mellitus (T2DM)
patients because of:
• its favorable cost-effectiveness ratio;
• a mechanism of action that is a logical approach for tar-
geting the major T2DM determinant of hepatic glucose
overproduction, driven by insulin resistance and/or portal
hypoinsulinaemia;
• its neutral or beneficial effects on weight;
• a rarity of serious drug-related adverse events;
• the mild and reversible nature of its more frequent side-effects.
On the other hand, by far the most common disadvantage
concerns the gastrointestinal (GI) system, as abdominal cramps
and/or changes in intestinal motility, leading to loose stools and
overt diarrhoea, sometimes uncontrollable [1–9].
For the majority of metformin-treated patients, GI symptoms
are absent or only temporarily seen to a moderate degree during
the initial titration period [6,7,10,11]. However, patients who are
unable to tolerate metformin are doubly disadvantaged due to,
first, the limited management of their diabetes and, second, their
high-risk phenotype [12]. They are missing out from the start
on a major therapeutic option and so are doomed to requiring
earlier insulin therapy. They also cannot take advantage of the
potentially beneficial effects of metformin on cardiometabolic
risk (CMR) conferred by the cellular and molecular mechanisms
of action of this AMP-activated protein kinase (AMPK) activator
[7,9].
For these reasons, it is logical to surmise that the T2DM
patients not able to benefit from metformin treatment because
of permanent discontinuation of the drug due to adverse GI
effects most likely have cardiovascular (CV) and metabolic
characteristics that are worse over time than those of T2DM
patients treated continuously by metformin. However, there are
at present no data on the phenotype of T2DM patients pre-
maturely weaned from metformin due to GI intolerance. The
present study was therefore designed to assess, without prereq-
uisites, the cardiometabolic characteristics of T2DM patients
according to GI (in)tolerance to metformin. The analyzed varia-
bles selected for the study, either belong to the definition, are
major determinants, are frequent comorbidities of the metabolic
syndrome (MetS) or T2DM, and/or are major CMR factors.
2.  Patients  and  methods
This cross-sectional study included 773 T2DM patients
[North-Caucasian (81%), North-African (8%) and Sub-Saharan
African (8%) ancestry] followed at St-Luc Hospital. Met-
formin intolerance ranging from intermittent/moderate to
severe/persistent was defined as the presence of diarrhoea and/or
GI dysmotility concomitant with medication intake that per-
sisted after uptitration beyond the first few weeks of drug
initiation in metformin-naïve patients. Intolerance was consid-
ered severe when, in addition, GI side-effects persisted even
with a substantially reduced dose (≥  50%), the intensity of
GI side-effects led to metformin withdrawal, and withdrawal
led to rapid and complete disappearance of the GI symptoms
[7,10].
Intolerance was documented in 182 T2DM patients (24%).
Among these cases, severe metformin intolerance resulting in
lifelong drug discontinuation was present in 83 (11%) patients
(Met-Intol). The remaining 591 (76%) with no GI intolerance
even at the highest dose (2550 mg/day) represented the con-
trol population. Of these metformin-tolerant (Met-Tol) patients,
14% had the drug subsequently interrupted for reasons unre-
lated to GI intolerance (such as a progressive decrease in
glomerular filtration rate or congestive heart failure) and were
considered controls. For every Met-Intol case (n  = 83), four age-
and gender-matched Met-Tol controls (n  = 332) were identi-
fied.
All cases and controls were evaluated according to age,
gender, diabetes duration, glycated haemoglobin (HbA1c),
socioeducational level (dichotomized as below high school vs.
otherwise), family history of early-onset coronary heart dis-
ease (CHD) [13], smoking habit, alcohol intake, handedness,
glucose-lowering/CV medications, body mass index (BMI),
waist circumference, fat mass, visceral fat and skeletal mus-
cle mass as measured by a body composition monitor (Omron
BF500, Omron Healthcare Europe B.V., Hoofddorp, The
Netherlands). The MetS was diagnosed according to the joint
interim report of Alberti et al. [14]. Insulin sensitivity and -cell
function were measured according to the updated homoeosta-
sis model assessment (HOMA2; http://www.dtu.ox.ac.uk)
[15].
Hypertension was defined as a systolic blood pres-
sure ≥  140 mmHg and/or diastolic blood pressure ≥  90 mmHg
and/or treatment with antihypertensive drugs. Diabetic retinopa-
thy was confirmed by fluorescein angiography. Peripheral
neuropathy was diagnosed using knee/ankle reflexes, the
© 2015 Elsevier Masson SAS. Tous droits réservés. - Document téléchargé le 17/06/2015 par UNIVERSITE CATHOLIQUE DE LOUVAIN  - (332310)
324 M.P. Hermans et al. / Diabetes & Metabolism 39 (2013) 322–329
Table 1
Patients’ characteristics.
Met tolerant Met intolerant P
n 332 83 ∼
Age Years 70 (13) 70 (13) ∼
Diabetes duration Years 17 (10) 17 (9) NS
HbA1c % 7.9 (1.5) 7.9 (1.4) NS
mmol.mol−1 62 (12) 63 (11) NS
Family history of premature CHD % 10 13 NS
Men % 46 46 ∼
Right-: non-right-handedness % 91:9 82:18 0.0262
Former smokers % 35 30 NS
Current smokers % 11 5 NS
Body mass index kg.m−2 30.3 (5.8) 30.3 (6.7) NS
Waist circumference cm 104 (14) 105 (15) NS
Fat mass % 35.2 (9.4) 35.1 (9.2) NS
Visceral fat 0–30 score 13 (4) 12 (5) NS
Insulin sensitivity (HOMA) % 56 (38) 44 (23) 0.0062
Metabolic syndrome % 86 86 NS
Hypertension % 91 90 NS
Systolic blood pressure mmHg 141 (19) 142 (21) NS
Diastolic blood pressure mmHg 79 (10) 80 (12) NS
ACE-I % 43 35 NS
ARB % 29 22 NS
CCB % 28 25 NS
BB % 33 35 NS
Diuretic % 41 37 NS
Statin % 66 48 0.0051
Fibrate % 19 18 NS
eGFR mL.min−1.1.73 m2 77 (27) 78 (27) NS
Albuminuria g.mg creatinine−1 66 (128) 78 (166) NS
Microangiopathy % 58 53 NS
DRP – PNP – erectile dysfunction % 27 – 28 – 52 23 – 28 – 47 NS
Results are expressed as means (SD) or proportions (%). ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: beta-blocker;
CCB: calcium-channel blocker; CHD: coronary heart disease; DRP: diabetic retinopathy; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin;
HOMA: homeostatis model assessment; Met: metformin; PNP: peripheral neuropathy; NS: non-significant.
Semmes–Weinstein monofilament test and/or electromyogra-
phy. Erectile dysfunction was diagnosed according to the present
authors’ previous reports [16,17]. Albuminuria was defined
as albumin excretion ≥  30 g.mg creatinine−1.1.73 m2 in the
first morning sample. Glomerular filtration rate was estimated
(eGFR) using the modification of diet in renal disease (MDRD)
study formula [18].
Coronary artery disease (CAD) was diagnosed as defined
in the present authors’ previous report [13] and by Gerber
et al. [19]. Stroke was defined according to the UK Prospective
Diabetes Study (UKPDS) criteria [20]. The presence of periph-
eral arterial disease (PAD) was described as applied elsewhere
[13].
ABO/Rhesus (Rh) blood group, fasting lipids [high-
density lipoprotein cholesterol (HDL-C)], triglycerides (TG),
apolipoprotein B100 (apoB), high-sensitivity C-reactive pro-
tein (hsCRP), fibrinogen, uric acid, white blood cells, iron,
transferrin, ferritin, folates and homocysteine were all deter-
mined. Low-density lipoprotein cholesterol (LDL-C) was
computed using Friedewald’s formula. Atherogenic dyslipi-
daemia (AD) prevalence and severity were defined as reported
elsewhere [12,21,22]. Each study participant gave their writ-
ten informed consent; the study was performed in agreement
with the declaration of Helsinki and principles of good
clinical practices, and the local ethics Institutional Review
Board.
2.1.  Statistical  methods
Results are presented as means and standard deviation (SD)
or as proportions (%). The significance of differences between
means was assessed by two-tailed Student’s t test or Welch’s test
and by Fisher’s exact test for differences in proportions, with
modified Bonferroni adjustments to minimize type 1 errors as a
result of multiple testing. Results were considered significant at
P < 0.05.
3.  Results
Patients’ characteristics are described in Table 1. Ethnogeo-
graphical extraction, diabetes duration and HbA1c were similar
in both Met-Tol and Met-Intol groups. In insulin-treated patients,
treatment duration before insulin was 11 (7) years in the Met-Tol
vs. 7 (6) years in the Met-Intol patients (P  < 0.0001).
In addition, 47% of patients had completed tertiary/university
degrees; the socioeducational levels were 58%/42% in the
Met-Tol vs. 53%/47% in the Met-Intol [not significant (NS)],
proportions reflecting the fact that St-Luc Hospital is located
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Table 2
Glucose-lowering therapy.
Met tolerant Met intolerant P
n 332 83 ∼
Metformin % 85 0 ∼
Metformin dose g.day−1 1.95 (0.54) ∼  ∼
ß-cell stimulant % 51 55 NS
Thiazolidinedione % 5 6 NS
Incretin-based therapiesa % 9 4 NS
Insulin % 45 60 0.0193
Insulin dose IU.day−1.kg−1 0.66 (0.46) 0.76 (0.82) NS
Oral monotherapy % 20 19 NS
Oral bitherapy % 32 10 < 0.001
Oral tritherapy % 1 0 NS
Oral therapy & insulin % 37 26 NS
Insulin monotherapy % 8 34 < 0.001
Results are expressed as means (SD) or proportions (%). Met: metformin. NS: non-significant.
a DPP4-I (dipeptidyl peptidase type 4 inhibitor) or GLP1-RA (glucagon-like peptide 1 receptor agonist) drugs.
in a prosperous district of Brussels and thus attended by gener-
ally well-educated/high-income patients. Current/past smoking
prevalences did not differ between groups, and alcohol intakes
were 12 (22) units/week in the Met-Tol vs. 12 (21) units/week
in the Met-Intol (NS). Leisure-time physical activity was also
not different between groups.
In all patients (n  = 773), non-right-handedness (left-
handedness and ambidexterity) was found in 12%. However,
there were twice as many non-right-handers among the Met-
Intol (18%) than Met-Tol (9%) patients (P  = 0.0262), with
left-handedness found in nearly one-fifth of the Met-Intol (100%
mean relative increase).
BMI, waist circumference, fat mass and visceral fat did not
differ between groups. Muscle mass was 29% (5) in both Met-
Tol and Met-Intol patients (NS), whereas insulin sensitivity was
lower (−12%) in the Met-Intol (P  = 0.0062). The MetS was
highly prevalent (86%) in both groups, with a MetS score of
3.9 (1.1) in Met-Tol vs. 3.7 (1.1) in Met-Intol patients (NS).
Hypertension prevalence was similar between groups, as were
systolic/diastolic blood pressure (BP) levels and the use of
BP-lowering agents. Non-alcoholic liver steatosis was detected
radiologically in 69% of Met-Tol vs. 80% of Met-Intol patients
(NS; Table 1).
Lipid-lowering drugs were used by 77% of Met-Tol vs. 58%
of Met-Intol (P  = 0.0008), while statins, fibrates and/or ezetim-
ibe were used by 66%, 19% and 5% of Met-Tol vs. 48%, 18% and
4% of Met-Intol, respectively (P  = 0.0051, NS and NS, respec-
tively). Statin monotherapy, fibrate monotherapy and statin plus
fibrate bitherapy were used by 54%, 10% and 8% of Met-Tol vs.
36%, 10% and 8% of Met-Intol, respectively (P  = 0.0183, NS
and NS, respectively). The greater use of statins in the Met-Tol
was related to higher CAD prevalence (data not shown). There
were no differences in eGFR, albuminuria, erectile dysfunction,
overall microangiopathy and organ-specific microangiopathy
between groups (Table 1).
Altogether, 85% of the Met-Tol were taking metformin at a
mean daily dose of 1.95 (0.54) g/day as monotherapy (18%)
or combined with a sulphonylurea (with or without insulin;
38%). There were no differences between groups in the use of
drugs with putative cardioprotective/cardiotoxic effects, includ-
ing -cell stimulants, thiazolidinediones and incretin-based
therapies. However, Met-Intol patients were more often treated
with insulin [as monotherapy or with an oral antidiabetic drug
(OAD)]. Insulin dosages were non-significantly higher in the
Met-Intol, who were also more often receiving insulin monother-
apy (Table 2).
LDL-C and apoB were also higher in the Met-Intol (Table 3).
Otherwise, there were no significant differences between groups
in HDL-C, TG, AD prevalence/severity and estimated LDL size.
The Met-Intol had lower leucocyte counts (relative −8%) with
higher iron indices, including greater iron, transferrin saturation
and ferritin levels (relative +12%, +17% and +64%, respec-
tively). There were no differences in hsCRP, fibrinogen, urate
and homocysteine levels between groups, although folates were
lower (mean −36%) in the Met-Intol.
ABO/Rh blood group distributions were: A (39.6%); B
(14.0%); AB (3.2%); and O (43.3%). Rates by subgroups
were: A Rh+ (34.3%); A Rh−  (5.3%); B Rh+ (12.8%); B
Rh− (1.2%); AB Rh+ (2.8%); AB Rh−  (0.4%); O Rh+
(37.5%); and O Rh−  (5.8%). Overall, the Rh+ frequency
was 87.4%. In the case–control comparison, the Met-Intol
more often belonged to group A and subgroup A Rh+, with
50% and 66% relative increases, respectively (P  = 0.0039 and
P = 0.0005, respectively). Group O and subgroup O Rh+
were each significantly underrepresented in the Met-Intol
by a relative 41% (P  = 0.0027 and P = 0.0049, respectively;
Fig. 1).
In the entire cohort, overall macroangiopathy was 32%,
comprising CAD (22%), PAD (8%) and/or transient ischaemic
attack (TIA)/stroke (9%). The Met-Intol had a markedly
lower prevalence of macrovascular disease (P  = 0.0486), with
the reduction mostly related to CAD (−34%; P = 0.0374)
and PAD (−44%; NS; Fig. 2). Differences in CHD were
seen in both groups irrespective of ferritin levels and ABO
grouping. However, after Bonferroni adjustments, the differ-
ences between groups were no longer significant for insulin
use, apoB, leucocytes, and serum iron and folates (data not
shown).
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Table 3
Laboratory values.
Met tolerant Met intolerant P
n 332 83
LDL-C mg.dL−1 92 (36) 102 (32) 0.0213
HDL-C mg.dL−1 49 (15) 49 (15) NS
Apolipoprotein B100 mg.dL−1 87 (27) 95 (27) 0.0162
Triglycerides mg.dL−1 178 (123) 168 (92) NS
Atherogenic dyslipidemia % 42 31 NS
Log(TG)/HDL-C 0.050 (0.020) 0.049 (0.018) NS
LDL-C/apolipoprotein B100 1.01 (0.30) 1.08 (0.26) NS
hsCRP mg.dL−1 0.39 (0.60) 0.38 (0.49) NS
Fibrinogen mg.dL−1 330 (77) 342 (79) NS
White blood cells 103.mm−3 7.39 (1.92) 6.82 (1.75) 0.0143
Neutrophiles % 58 (9) 57 (9) NS
Lymphocytes % 30 (9) 31 (8) NS
Iron g.dL−1 85 (31) 95 (34) 0.0103
Transferrin mg.dL−1 282 (48) 265 (44) 0.0035
Transferrin saturation % 22.0 (9.9) 25.8 (9.3) 0.0017
Ferritin g.L−1 124 (137) 203 (176) < 0.001
Folic acid ng.mL−1 9.4 (12.9) 6.0 (3.4) 0.0178
Results are expressed as means (SD) or proportions (%). LDL-C/HDL-C: low-density lipoprotein/high-density lipoprotein cholesterol; hsCRP: high-sensitivity
C-reactive protein; Met: metformin; TG: triglycerides (triacylglycerols); NS: non-significant.
4.  Discussion
It is still not known whether treating diabetes without the
use of metformin leads to altered CV outcomes. However, the
main findings of our present study were fourfold: metformin
GI intolerance was associated with a lower prevalence of CAD;
and there were also an ABO blood group imbalance, higher
ferritin levels and brain function lateralization leaning towards
left-handedness.
There is still some debate over whether AMPK activation
by metformin improves vascular outcomes beyond the benefi-
cial effects of glucose-lowering on small vessels [5,8,9]. In fact,
in our Met-Intol patients, lifelong drug discontinuation did not
result in the emergence of a negative CMR phenotype, but was
instead related to a lower prevalence of all-cause macroangiopa-
thy and ischaemic heart disease. Indeed, it cannot be ruled out
from a transverse study that some as yet unidentified cardiopro-
tective determinants are either mechanistically or incidentally
related to GI intolerance, nor can a survival bias be excluded.
Unrecognized cardiotoxic factors may be related to long-term
metformin use, or metformin may prove to be not as beneficial
as is generally thought. This confounding effect (lower CHD
prevalence among Met-Intol patients) could thus far have been
hindering the unambiguous detection of long-term cardiopro-
tection with metformin.
There were no differences between groups regarding the
use of glucose-lowering drugs purporting to have cardiopro-
tective properties (thiazolidinediones, incretin-based therapies)
or cardiotoxic side-effects (sulphonylureas, thiazolidinediones),
yet almost 40% of metformin-treated T2DM patients also
received sulphonylureas, a combination that is widely recom-
mended despite concerns that it might increase the risk of CHD
[6,23–28]. Met-Intol patients were less often treated with lipid-
lowering drugs, most likely as a result of lower CAD prevalence.
The Met-Intol also had significantly lower leucocyte counts,
which was in agreement with previous reports linking raised
white cell counts with CAD risk [29].
There is a growing body of evidence in the literature, albeit
disparate, concerning CHD risk and ABO blood groups [30–34].
The present study sheds some light on a previously unreported
interaction between ABO grouping and CHD prevalence in
T2DM, albeit with no grounds on which to base a mechanistic
hypothesis. As regards the GI tract, a correlation between ABO
blood group and relative proportions of healthy GI microbiota
was recently reported [35].
Although the underlying cause(s) of GI symptoms due to
metformin is still unclear, digestive intolerance remains a major
limiting factor for optimizing glucose-lowering therapy, par-
ticularly when starting treatment and during uptitration [7].
In addition, it cannot be excluded that metformin may alter
the intestinal flora especially by inducing mild sugar mal-
absorption with carbohydrate displacement to distal parts of
the GI tract, resulting in local/systemic changes in incretins,
serotonin, ghrelin and bile salt handling, all considered to be
CV risk modulators [36]. Metformin-induced GI malabsorption
of macro-/micronutrients has also been reported with sugars,
folates and vitamin B12, occasionally leading to hyperhomo-
cysteinaemia [11,37].
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P  = 0.003 9
NS
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Fig. 1. Frequency of ABO and Rhesus blood groups in metformin-tolerant (gray;
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Fig. 2. Prevalence of macroangiopathy in metformin-tolerant (gray; n = 332) and
metformin-intolerant (black; n = 83) type 2 diabetes patients. CAD: coronary
artery disease; PAD: peripheral artery disease; TIA: transient ischaemic attack;
NS: not significant. P = 0.0486 (macroangiopathy); P = 0.0374 (CAD); NS (PAD
and TIA/stroke).
Hyperferritinaemia in T2DM is linked to a decreased
CHD prevalence despite more severe insulin resistance (IR)
and markers of non-alcoholic steatohepatitis, suggesting that
higher ferritin levels and/or steatosis may paradoxically be
conferring a lower risk of CV in T2DM patients [38–40]. Met-
formin can lower ferritin through different mechanisms either
directly or indirectly through less hyperinsulinaemia and liver
fat deposition. A link between metformin and ferritin was
recently described in cardiomyocytes [41]. However, to our
knowledge, no association between GI tolerability, iron absorp-
tion/load and metformin on the one hand, and lower iron-related
indices on the other hand, has been reported. As ferritin is
a natural antioxidant, it may be speculated that such differ-
ences could unexpectedly confer vascular benefit to Met-Intol
patients.
It has previously been reported that non-right-handedness
can modulate the cardiometabolic phenotype of T2DM in Cau-
casians [42]. Fujiwara et al. [43] reported a negative association
between left-handedness and satiation, raising the possibil-
ity that brain lateralization might affect the incidence and
expression of GI symptoms. This observation is all the more
challenging as our group has observed a higher prevalence
of left-handers in Met-Intol patients than in the general or
T2DM population [42]. Although the separate components
of the intolerance phenotype may appear to be mutually
unrelated, each has previously been described as modulating
CMR. Their joint presence fostered by metformin intoler-
ance may be contributing to a lower CVD prevalence. At
the cellular level, an association between genetic variations in
organic cation transporters [such as OCT1, OCT2, and mul-
tidrug and toxin extrusion protein 1 (MATE1)] genes and
metformin GI side effects has also been reported in T2DM
[44].
One clear limitation of our present study, which mostly
included Caucasians, lies in its cross-sectional design, which
should be extended to include diabetics of other ethnicities.
Another limitation is the lack of data for accumulated met-
formin exposure in our two patient groups. In Met-Tol patients,
the mean duration of use was most likely similar to their
known diabetes duration, as metformin is almost invariably
introduced as the first oral treatment once therapeutic lifestyle
changes fails. Its early implementation is decided on the basis
of its:
• low cost, general safety and the fact that all recommendations
advocate its use as the first-line OAD;
• hitherto alleged beneficial effects on CMR;
• virtual inability to cause hypoglycaemia when used on its
own;
• frequent, albeit modest, slimming effects that are apparently
related to mild appetite loss.
In the present study, those patients with low-to-moderate GI
tolerance to metformin who continued to take the medication
at a reduced/normal dose despite experiencing GI side-effects
were excluded. In these cases, intolerance was either:
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•  weak in intensity;
• acceptable in view of the achieved HbA1c reduction;
• offset by a consensual decision to keep using the drug, but at
a reduced dose.
The study design thus allowed comparison of two distinct
groups—tolerant patients with long-term exposure to metformin
at the recommended dose vs. patients with the most severe form
of GI intolerance (early in onset and at every dosage) who had
insignificant drug exposure in terms of duration or cumulative
dose.
In conclusion, highlighting metformin intolerance in T2DM
patients has revealed a phenotype as unexpected as it is complex,
and characterized by a lower rate of ischaemic heart disease, left-
handedness, blood group A and iron loading. Uncovering how
GI intolerance to metformin is associated with a lower CAD
prevalence and how the seemingly heterogeneous parts of the
phenotype interconnect could help to further characterize CMR
in T2DM. Prospective studies are now required to confirm our
observations.
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